Executive SummaryJerry Karabelas becomes VP-marketing of the company's U.S. prescription drug business effective June 27. Karabelas originally joined SmithKline in 1982, eventually becoming a group VP for gastrointestinal products. He left the firm in December 1989 to become CEO of Cellular Transplants Inc., a Providence, Rhode Island-based biotech firm. In his new position at SmithKline Beecham, Karabelas will replace Roger Ross, a 25-year SmithKline veteran who has decided to leave the company. The VP-marketing position currently reports to Fred Kyle, who heads U.S. pharmaceutical operations. However, the company is seeking a replacement for Kyle, who was recently given overall responsibility for worldwide manufacturing.
You may also be interested in...
Abbott is encouraged by results from two studies of its Proclaim XR neurostimulation system for chronic pain, presented at the annual North American Neuromodulation Society (NANS) meeting in Las Vegas. See what Steven Falowski of Neurosurgical Associates of Lancester in Pennsylvania said about it here.
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
According to the plaintiff, Unilever’s Pond’s Rejuveness Anti-Wrinkle Cream is defective insofar as tested product has been found to contain unlabeled mercury, constituting negligence that has resulted in user injuries. The plaintiff seeks certification of a transnational class and compensatory and punitive damages, among other relief.